IP Library Granted Patent US 8,268,572
Granted Patent B2
US 8,268,572 · App. 11/884,800 · Granted Sep 18, 2012

Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels

Assignees: Dana-Farber Cancer Institute, Inc.; The General Hospital Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,572
App. No.
11/884,800
Granted
Sep 18, 2012
Kind
B2
Abstract

Methods are provided for identifying candidate agents for use in inhibiting expression of certain receptors and ion channels in nociceptors. Also provided are methods for identifying candidates agents for use in inhibiting neurophathic and other types of pain.

Claims (32)

1. A method for identifying a candidate inhibitor of runt-related transcription factor 1 (Runx1)-mediated expression of a nociceptive receptor or ion channel, the method comprising

contacting a test cell that expresses Runx1 and comprises a nucleic acid encoding a nociceptive receptor or ion channel operatively linked to a Runx1-sensitive promoter, with a test agent;

measuring a test amount of expression of the nociceptive receptor or ion channel;

comparing the test amount of expression of the nociceptive receptor or ion channel to a control amount of expression of the nociceptive receptor or ion channel measured in a control cell that expresses Runx1 and comprises the nucleic acid encoding the nociceptive receptor or ion channel operatively linked to the Runx1-sensitive promoter, wherein the control cell is not contacted with the test agent; and

identifying the test agent as a candidate inhibitor of Runx1-mediated expression of a nociceptive receptor or ion channel when the control amount of expression of the nociceptive receptor or ion channel is greater than the test amount of expression of the nociceptive receptor or ion channel.

2. The method of claim 1 , wherein the nucleic acid encoding the nociceptive receptor or ion channel operatively linked to the Runx1-sensitive promoter encodes a nociceptive receptor or ion channel chosen from TRPC3, TRPM8, TRPA1, Mrgprd, P2X3, Nav1.9/SNS2, TRPV1, TRPV2, Mrgpra1, Mrgpra2, Mrgpra3, Mrgpra6, Mrgprb4, Mrgprb5 and any combination thereof.

3. The method of claim 1 , wherein the test cell comprises a Runx1 expression vector.

4. The method of claim 1 , wherein the control cell comprises a Runx1 expression vector.

5. The method of claim 1 , wherein the test amount of expression of the nociceptive receptor or ion channel and the control amount of expression of the nociceptive receptor or ion channel are corresponding amounts of transcript for the nociceptive receptor or ion channel.

6. The method of claim 1 , wherein the test amount of expression of the nociceptive receptor or ion channel and the control amount of expression of the nociceptive receptor or ion channel are corresponding amounts of protein for the nociceptive receptor or ion channel.

7. The method of claim 1 , wherein the nucleic acid encoding the nociceptive receptor or ion channel operatively linked to the Runx1-sensitive promoter is part of an expression vector.

8. The method of claim 1 , wherein the control cell is a dorsal root ganglion cell derived from a Runx1F/F; Wnt1-Cre mouse.

9. The method of claim 1 , wherein the test compound is selected from the group consisting of small molecules, peptides, nucleic acids, and any combination thereof.

10. The method of claim 1 , wherein the test compound is a small molecule.

11. The method of claim 1 , wherein the test compound is a nucleic acid.

12. The method of claim 1 , wherein the test compound inhibits expression of Runx1.

13. A method for identifying a candidate agent for use in inhibiting neuropathic pain, the method comprising

contacting a test cell that expresses runt-related transcription factor 1 (Runx1) and comprises a nucleic acid encoding a nociceptive receptor or ion channel operatively linked to a Runx1-sensitive promoter, with a test agent;

measuring a test amount of expression of the nociceptive receptor or ion channel;

comparing the test amount of expression of the nociceptive receptor or ion channel to a control amount of expression of the nociceptive receptor or ion channel measured in a control cell that expresses Runx1 and comprises the nucleic acid encoding the nociceptive receptor or ion channel operatively linked to the Runx1-sensitive promoter, wherein the control cell is not contacted with the test agent; and

identifying the test agent as a candidate agent for use in inhibiting neuropathic pain when the control amount of expression of the nociceptive receptor or ion channel is greater than the test amount of expression of the nociceptive receptor or ion channel.

14. The method of claim 13 , wherein the nucleic acid encoding the nociceptive receptor or ion channel operatively linked to the Runx1-sensitive promoter encodes a nociceptive receptor or ion channel chosen from TRPC3, TRPM8, TRPA1, Mrgprd, P2X3, Nav1.9/SNS2, TRPV1, TRPV2, Mrgpra1, Mrgpra2, Mrgpra3, Mrgpra6, Mrgprb4, Mrgprb5 and any combination thereof.

15. The method of claim 13 , wherein the test cell comprises a Runx1 expression vector.

16. The method of claim 13 , wherein the control cell comprises a Runx1 expression vector.

17. The method of claim 13 , wherein the test amount of expression of the nociceptive receptor or ion channel and the control amount of expression of the nociceptive receptor or ion channel are corresponding amounts of transcript for the nociceptive receptor or ion channel.

18. The method of claim 13 , wherein the test amount of expression of the nociceptive receptor or ion channel and the control amount of expression of the nociceptive receptor or ion channel are corresponding amounts of protein for the nociceptive receptor or ion channel.

19. The method of claim 13 , wherein the nucleic acid encoding the nociceptive receptor or ion channel operatively linked to the Runx1-sensitive promoter is part of an expression vector.

20. The method of claim 13 , wherein the control cell is a dorsal root ganglion cell derived from a Runx1F/F; Wnt1-Cre mouse.

21. The method of claim 13 , wherein the test compound is selected from the group consisting of small molecules, peptides, nucleic acids, and any combination thereof.

22. The method of claim 13 , wherein the test compound is a small molecule.

23. The method of claim 13 , wherein the test compound is a nucleic acid.

24. The method of claim 13 , wherein the test compound inhibits expression of Runx1.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 26, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039462/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2007
From: WOOLF, CLIFFORD J.; BROOM, DANIEL C.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 020255/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2007
From: MA, QIUFU; CHEN, CHIH-LI
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 020255/0986 →
Continuity (2)
Provisional Application 60658824 · Mar 4, 2005
Related Publication 20090170079A1 · Jul 2, 2009